MM PD market growth will be driven by advancements in innovative therapies, including the first DMTs, and a growing patient ...

In last year's update, AbbVie raised the combined 2027 net sales guidance for Skyrizi and Rinvoq by $6 billion to $27 billion ...

AbbVie ABBV is set to report fourth-quarter and full-year 2024 earnings on Jan. 31, before the opening bell. The Zacks ...

AbbVie has finally claimed FDA approval for its advanced Parkinson's disease therapy Vyalev, 18 months after the US regulator turned it down with a request for more data. Now, Vyalev (foscarbidopa ...

Sneak peek at San Diego community events street fairs, festivals, concerts, performances, art shows, community meetings ...

AbbVie’s ABBV stock has declined 8% in the past three months.A lot of this price decline is due to the poor performance of the overall drug and biotech sector in the past couple of months after ...

DelveInsight's Parkinson's Disease Levodopa-induced Dyskinesia Market report offers an in-depth understanding of the epidemiology and market trends in the 7MM. LAS VEGAS, NV, UNITED STATES ...